European Pharmacopoeia Overview
What is the European Pharmacopoeia?
The European Pharmacopoeia (Ph. Eur.) is Europe's official book of legally binding quality standards for medicines and their ingredients. It is drawn up under the Council of Europe's 1964 Convention on the Elaboration of a European Pharmacopoeia and published by the EDQM (European Directorate for the Quality of Medicines & HealthCare). Where a Ph. Eur. requirement exists, raw materials, preparations, dosage forms and containers must meet it. All of this comes from an EMA-hosted EDQM presentation and the Italian Permanent Representation to the Council of Europe, both linked below.
Legal basis and status
- The Convention: It was opened for signature in Strasbourg on 22 July 1964. It was amended by a Protocol that came into force on 1 November 1992 (Italian Permanent Representation to the CoE).
- One standard across members: The EDQM describes the Ph. Eur. as "one common compulsory standard". It is "the official pharmacopoeia in Europe" and becomes mandatory on the same date in all member states. National pharmacopoeias add texts that matter to only one member state (EMA/EDQM presentation, slide 3).
- Membership: 37 Council of Europe states plus the European Union. There are also 26 observer states (18 of them outside the Council of Europe), Taiwan's FDA and the WHO (Italian Permanent Representation).
- What it covers: The composition of, and tests for, medicines, the raw materials used to make them, and intermediate products. It acts as the legal basis for quality control during development, production and marketing (same source).
What is in it (EMA/EDQM presentation, slides 4–19)
- Individual monographs: These cover active substances, excipients, biologicals and biotech products, herbal drugs, radiopharmaceuticals, vaccines and sera, blood derivatives and homeopathic preparations. The presentation counts "more than 2200 monographs". It is an older, undated deck (it quotes the 8th edition), so that figure may be out of date.
- General Notices: These apply to every text and must be read before using any monograph. An article is "not of Pharmacopoeia quality unless it complies with all the requirements stated in the monograph". That does not mean a manufacturer has to run every test before releasing a product.
- General monographs: Some cover classes of substance, such as 2034 Substances for pharmaceutical use, which applies to all active substances whether or not they have their own monograph. Others cover dosage forms such as tablets and parenterals. They apply without being cross-referenced, and they complement individual monographs rather than override them.
- General chapters: These describe analytical methods and other topics. They are not mandatory in themselves, but become part of the standard when a monograph refers to them. For example, chapter 5.2.8 on TSE risk is legally binding through general monograph 1483.
- Alternative methods: Ph. Eur. tests are the reference methods in a dispute. Other methods may be used if they give the same pass/fail result; the user must show they are suitable, and the competent authority often has to approve them.
Related EDQM activities
- Certificates of Suitability (CEPs): A CEP confirms that a substance's quality is adequately controlled by its Ph. Eur. monograph, or that it meets the TSE requirements. Under Directive 2003/63/EC, a CEP replaces the corresponding data in a marketing authorisation dossier. A CEP is neither a certificate of analysis nor a GMP certificate (slides 20–27).
- International harmonisation: The Ph. Eur. works with the Japanese Pharmacopoeia and the USP in the Pharmacopoeial Discussion Group, with the WHO as an observer, to harmonise general chapters (slide 13).
Approach: I checked the datasets, which hold EDQM laboratory-testing reports and the Norwegian Ph. Eur. monograph list but no overview of the Pharmacopoeia itself. I then used an EDQM presentation hosted by EMA and the Italian Permanent Representation to the Council of Europe. The EDQM's own website refused access, so I couldn't confirm the current edition number or monograph count from it.
Which edition is current now?
The 12th Edition of the European Pharmacopoeia is current. The latest supplement I found is Ph. Eur. 12.3: published January 2026 and in effect since 1 July 2026 [1].
The Ph. Eur. 12 supplements in the Norwegian Medical Products Agency's (DMP) monograph list:
| Supplement | Published | Effective |
|---|---|---|
| Ph. Eur. 12.1 | July 2025 | 1 January 2026 [2] |
| Ph. Eur. 12.2 | October 2025 | 1 April 2026 [3] |
| Ph. Eur. 12.3 | January 2026 | 1 July 2026 [1] |
Each supplement takes effect about six months after it is published.
The list contains no entries for any supplement after 12.3, and none for a 13th Edition. Its entries all show the monograph version currently in force, so most are dated 12.1 (for example, azithromycin, monograph 1649 [4]). Only monographs revised later are dated 12.2 or 12.3.
Approach: I used the DMP's Ph. Eur. monograph list, which covers only monographs that have a Norwegian name. The EDQM's own site wasn't reachable last time, so I haven't confirmed from the EDQM whether a supplement after 12.3 came into force in October 2026.
How is it different from the USP?
The main difference is how each one becomes law. The Ph. Eur. is an intergovernmental standard: the EDQM publishes it under a Council of Europe convention, and EU law applies it directly through Directive 2001/83/EC. The USP is published by a private body, the United States Pharmacopeial Convention, Inc., and gets its force because the US Federal Food, Drug, and Cosmetic Act (FD&C Act) names it an "official compendium". The technical content overlaps a lot, and the two pharmacopoeias already work to harmonise it.
| European Pharmacopoeia | USP (with the National Formulary) | |
|---|---|---|
| Publisher | EDQM, under the 1964 Council of Europe Convention (from the previous answer); Directive 2001/83 refers to the EDQM as the "standardisation body" under that Convention [5] | The United States Pharmacopeial Convention, Inc., "publisher of the United States Pharmacopeia and the National Formulary" (FDA MOU 225-83-3000) |
| How it becomes binding | Its monographs "shall be applicable to all substances, preparations and pharmaceutical forms appearing in it" [6]. For the quality part of a dossier, all monographs, general monographs and general chapters apply [7] | The FD&C Act defines "official compendium" as the USP, the Homoeopathic Pharmacopoeia of the United States (HPUS), the National Formulary, and their supplements (21 U.S.C. 321(j)) [8] |
| What happens if a product doesn't comply | Compliance is assessed through the marketing authorisation dossier (Module 3 of Annex I) | Enforced as adulteration: a drug with a compendial name whose strength, quality or purity falls below the compendial standard, judged by the compendium's own tests, is adulterated (21 U.S.C. 351(b)). Packaging and labelling not as the compendium prescribes is misbranding (21 U.S.C. 352(g)) [9][10] |
| Departing from the standard | I found no counterpart to the US labelling exception in Directive 2001/83 | A drug is not adulterated under 351(b) if its difference from the standard is "plainly stated on its label" [9] |
| When the standard is inadequate | Competent authorities may ask the marketing authorisation holder for tighter specifications and must inform the pharmacopoeia authority; uncontrolled impurities must be declared [6] | The FDA must refer the problem to the body that revises the compendium. If that body does not act within a reasonable time, the FDA may set test methods by regulation [9] |
| Official names | The usual name for an ingredient is the Ph. Eur. monograph title, or failing that a national pharmacopoeia title, then the INN [11] | The "established name" is the official name, or failing that the compendial title, then the common name (21 U.S.C. 352(e)(3)) [10] |
| Homeopathic products | Inside the Ph. Eur.: a homeopathic product is defined by reference to Ph. Eur. manufacturing procedures [12] | A separate compendium, the HPUS. A drug listed in both follows the USP unless it is labelled and sold as homeopathic [9] |
| Reach beyond medicines | Its role in Directive 2001/83 is the quality of medicinal products | Recognition in the USP or NF is one way an article meets the statutory definition of a "drug", and also of a "device" (21 U.S.C. 321(g)(1) and (h)) [8] |
| Certification route | Certificates of Suitability (CEPs) from the EDQM replace the matching dossier data [13]. The EDQM can ask for inspections linked to CEPs [5] | I found no counterpart in the FD&C Act sections I checked |
Using USP monographs in the EU: The Ph. Eur. comes first, then a member state's national pharmacopoeia. A third-country pharmacopoeia such as the USP can be accepted only for materials described in neither [6][13]. Where a Ph. Eur. monograph exists, EU dossiers must meet it, and Ph. Eur. reference standards should be used where relevant [11].
Harmonisation: The EDQM presentation from the first answer says the Ph. Eur., the USP and the Japanese Pharmacopoeia harmonise general chapters through the Pharmacopoeial Discussion Group, with the WHO as an observer.
I couldn't confirm the USP's current edition, revision schedule or monograph count.
Approach: I read the consolidated Directive 2001/83/EC and the FD&C Act (21 U.S.C. chapter 9, 2023 US Code edition), plus an FDA memorandum of understanding with the USP. The USP's own website refused access.